NCT01535040 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity. memantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
- id
- FG000
- title
- Arm I - Memantine
- description
- Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity. placebo: Placebo by mouth through completion of 12 weeks.
- id
- FG001
- title
- Arm II - Placebo
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 13
- group Id
- FG001
- num Subjects
- 10
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 9
- group Id
- FG001
- num Subjects
- 4
- type
- Never Started
- reasons
- group Id
- FG000
- num Subjects
- 7
- group Id
- FG001
- num Subjects
- 5
- type
- Toxicity
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- type
- Multiple Reasons
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 65
- group Id
- FG001
- num Subjects
- 65
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 35
- group Id
- FG001
- num Subjects
- 44
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 30
- group Id
- FG001
- num Subjects
- 21
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity. memantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
- id
- FG000
- title
- Arm I - Memantine
- description
- Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity. placebo: Placebo by mouth through completion of 12 weeks.
- id
- FG001
- title
- Arm II - Placebo
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 13
- group Id
- FG001
- num Subjects
- 10
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 9
- group Id
- FG001
- num Subjects
- 4
- type
- Never Started
- reasons
- group Id
- FG000
- num Subjects
- 7
- group Id
- FG001
- num Subjects
- 5
- type
- Toxicity
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- type
- Multiple Reasons
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 65
- group Id
- FG001
- num Subjects
- 65
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 35
- group Id
- FG001
- num Subjects
- 44
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 30
- group Id
- FG001
- num Subjects
- 21
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle